Immunovant’s

Immunovant’s

Developing transformative therapies for autoimmune diseases with the goal of redefining outcomes for those affected by these conditions. Learn more

Launch date
Employees
Market cap
€3.9b
Enterprise valuation
€3.4b (Public information from Sep 2024)
New York City New York (HQ)
Authorizing premium user...